Zobrazeno 1 - 10
of 1 422
pro vyhledávání: '"Jones KN"'
Autor:
Jacob Jones, K Nicole Jones
Publikováno v:
Substance Abuse: Research and Treatment, Vol 13 (2019)
With the broadening legislative changes surrounding legalized recreational marijuana in the United States, tracking the impact of such changes is imperative. As such, in a recent article published in Addictive Behaviors , we identified several emergi
Externí odkaz:
https://doaj.org/article/599dca07909d4f55a240ee59ee6c17b7
Autor:
Jones J; Social and Behavioral Sciences, Colorado Mesa University, Grand Junction, CO, USA., Jones KN; Social and Behavioral Sciences, Colorado Mesa University, Grand Junction, CO, USA.
Publikováno v:
Substance abuse : research and treatment [Subst Abuse] 2019 Feb 07; Vol. 13, pp. 1178221819827603. Date of Electronic Publication: 2019 Feb 07 (Print Publication: 2019).
Autor:
Jacob, Jones, K Nicole, Jones
Publikováno v:
Substance Abuse: Research and Treatment
In January of 2014 the Regulate Marijuana like Alcohol Act or, Amendment 64, went into effect in Colorado. Even though it was the first state to enact recreational legalization, attitudes towards marijuana use have been changing for decades. Prompted
Autor:
Englander, B.S., Khurana, A.
Publikováno v:
Breast Diseases: A Year Book Quarterly; 2014, Vol. 25 Issue 4, p316-317, 2p
Autor:
Sakuma Y; Faculty of Medicine, School of Public Health, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK. y.sakuma.hi@gmail.com., Miller MLE; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, Stadium House, 68 Wood Ln, London, W12 7RH, UK., Babalis DS; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, Stadium House, 68 Wood Ln, London, W12 7RH, UK., Baker A; Imperial Clinical Trials Unit - Cancer, Department of Surgery and Cancer, Convergence Science Centre, Imperial College London, South Kensington Campus, London, Cancer Research, SW7 2AZ, UK., Reddi M; Imperial Clinical Trials Unit - Cancer, Department of Surgery and Cancer, Convergence Science Centre, Imperial College London, South Kensington Campus, London, Cancer Research, SW7 2AZ, UK., Anjum A; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, Stadium House, 68 Wood Ln, London, W12 7RH, UK., Bruton J; Patient Experience Research Centre, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK., Jones KN; Patient Experience Research Centre, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK., Mulla UZ; Faculty of Medicine, School of Public Health, Medical School, Imperial College London, St Mary's Campus, 167, Praed Street, London, W2 1NY, UK., Taddese H; Faculty of Medicine, School of Public Health, Medical School, Imperial College London, St Mary's Campus, 167, Praed Street, London, W2 1NY, UK.
Publikováno v:
Trials [Trials] 2024 Apr 26; Vol. 25 (1), pp. 281. Date of Electronic Publication: 2024 Apr 26.
Autor:
El-Khawaldeh R; Department of Chemistry, University of British Columba Vancouver BC Canada jhein@chem.ubc.ca., Guy M; Department of Chemistry, University of British Columba Vancouver BC Canada jhein@chem.ubc.ca., Bork F; Department of Chemistry, University of British Columba Vancouver BC Canada jhein@chem.ubc.ca., Taherimakhsousi N; Department of Chemistry, University of British Columba Vancouver BC Canada jhein@chem.ubc.ca., Jones KN; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Hawkins JM; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Han L; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Pritchard RP; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Cole BA; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Monfette S; Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA Sebastien.Monfette@pfizer.com., Hein JE; Department of Chemistry, University of British Columba Vancouver BC Canada jhein@chem.ubc.ca.; Acceleration Consortium, University of Toronto Toronto ON Canada.; Department of Chemistry, University of Bergen Bergen Norway.
Publikováno v:
Chemical science [Chem Sci] 2023 Nov 27; Vol. 15 (4), pp. 1271-1282. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2024).
Autor:
Jones KN; Department of Social and Behavioral Sciences, Colorado Mesa University, Grand Junction, Colorado, USA., Hoover S; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Glaeser E; Department of Counseling and Clinical Psychology, Teachers College, Columbia University, New York, New York, USA., Woods CJ; Department of Educational Leadership, Northern Arizona University, Flagstaff, Arizona, USA., Clark M; Department of Social and Behavioral Sciences, Colorado Mesa University, Grand Junction, Colorado, USA., Brewster M; Department of Counseling and Clinical Psychology, Teachers College, Columbia University, New York, New York, USA.
Publikováno v:
Journal of homosexuality [J Homosex] 2022 Jul 29; Vol. 69 (9), pp. 1501-1523. Date of Electronic Publication: 2021 May 18.
Autor:
Omar MH; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: mho6@uw.edu., Byrne DP; Department of Biochemistry & Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK., Jones KN; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Lakey TM; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Collins KB; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Lee KS; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Daly LA; Centre for Proteome Research, Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK., Forbush KA; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Lau HT; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Golkowski M; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., McKnight GS; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Breault DT; Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA., Lefrançois-Martinez AM; Génétique, Reproduction et Développement (GReD), CNRS, INSERM, Université Clermont Auvergne, 63001 Clermont-Ferrand, France., Martinez A; Génétique, Reproduction et Développement (GReD), CNRS, INSERM, Université Clermont Auvergne, 63001 Clermont-Ferrand, France., Eyers CE; Centre for Proteome Research, Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK., Baird GS; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA., Ong SE; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Smith FD; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA., Eyers PA; Department of Biochemistry & Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK., Scott JD; Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: scottjdw@uw.edu.
Publikováno v:
Cell reports [Cell Rep] 2022 Jul 12; Vol. 40 (2), pp. 111073.
Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial
Autor:
Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, Moccetti T, Rossi MG, AnesiniA A, Allemano P, Reynaud SG, Fenoil R, Giannuzzi P, Corrà U, Gavazzi A, Grosu A, Volpi A, Jones KN, Lissi C, Turazza FM, Frigerio M, Febo O, Olmett F, Cirò A, Vincenzi A, Scelsi L, Campana C, Opasich C, Gualco A, Iannone MA, Cucchi G, Catania G, Tarantini L, Rigatelli G, Boni S, Carlon R, Sacchetta A, Borgese L, Sarto P, Milan S, Milan D, Roncon L, Carraro M, Rossi R, Carbonieri E, Valentini A, Brighetti G, Cantarelli A, Ferrari R, FuciliF A, Bonfiglioli A, Mariani PR, Martinelli S, Buccolieri M, Moretti L, Partemi L, Gregori G, Testa D, Pulignano G, Santini M, Varveri A, Aspromonte N, Staniscia D, Calgione E, Vetrano A, Pettinati G, Ciricugno S, Gualtieri MR, Villella M, Lauletta R, Tagliamonte E, Scozzafava A, Cassano S, Misuraca G, Caporale R, Musca G, Carpino C, Leonardi G, Ledda G, Di Tano G, Cirrincione V, Sanfilippo N, Enia F, Floresta M, Porcu M, Orrù P., PERRONE FILARDI, PASQUALE
Publikováno v:
On behalf of the GISSI-HF Investigators, Denmark 2010, ' Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial ', European Journal of Heart Failure, vol. 12, no. 6, pp. 549-56 . https://doi.org/10.1093/eurjhf/hfq055
Udgivelsesdato: 2010 AIMS: To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). METHODS AND RESULTS: Plasma CgA levels were measured at randomizati
Autor:
Wong CK; Department of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA., Rissland MS; Program in Physical Therapy, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA., Madagan DM; Program in Physical Therapy, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA., Jones KN; Program in Physical Therapy, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Publikováno v:
Physical therapy [Phys Ther] 2021 Aug 01; Vol. 101 (8).